These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1037 related items for PubMed ID: 19738369

  • 1. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N, Kalaitzidis R, Bakris GL.
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [Abstract] [Full Text] [Related]

  • 2. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
    Gwoo S, Kim YN, Shin HS, Jung YS, Rim H.
    Nephron Clin Pract; 2014; 128(3-4):381-6. PubMed ID: 25572273
    [Abstract] [Full Text] [Related]

  • 3. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B.
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, EMPHASIS-HF Investigators.
    J Am Coll Cardiol; 2013 Oct 22; 62(17):1585-93. PubMed ID: 23810881
    [Abstract] [Full Text] [Related]

  • 5. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
    Bianchi S, Bigazzi R, Campese VM.
    Kidney Int; 2006 Dec 22; 70(12):2116-23. PubMed ID: 17035949
    [Abstract] [Full Text] [Related]

  • 6. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 22; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 7. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
    Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA.
    J Hum Hypertens; 2012 Aug 22; 26(8):502-6. PubMed ID: 21677673
    [Abstract] [Full Text] [Related]

  • 8. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
    Agarwal R, Rossignol P, Garza D, Mayo MR, Warren S, Arthur S, Romero A, White WB, Williams B.
    Am J Nephrol; 2018 Aug 22; 48(3):172-180. PubMed ID: 30176673
    [Abstract] [Full Text] [Related]

  • 9. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators.
    Circulation; 2008 Oct 14; 118(16):1643-50. PubMed ID: 18824643
    [Abstract] [Full Text] [Related]

  • 10. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
    Gluhovschi G, Mateş A, Gluhovschi C, Golea O, Gădălean F, Somai M, Ene I, Petrica L, Velciov S.
    Rom J Intern Med; 2014 Oct 14; 52(1):30-8. PubMed ID: 25000676
    [Abstract] [Full Text] [Related]

  • 11. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep 14; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 12. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E, Gutiérrez E, Caro J, Sevillano A, Rojas-Rivera J, Praga M.
    Nefrologia; 2015 Sep 14; 35(6):554-61. PubMed ID: 26519114
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension.
    Calhoun DA, White WB.
    J Am Soc Hypertens; 2008 Sep 14; 2(6):462-8. PubMed ID: 20409927
    [Abstract] [Full Text] [Related]

  • 14. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF.
    Eur J Prev Cardiol; 2014 Mar 14; 21(3):299-309. PubMed ID: 24191305
    [Abstract] [Full Text] [Related]

  • 15. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB.
    J Am Soc Hypertens; 2012 Mar 14; 6(5):338-45. PubMed ID: 22995802
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Beneficial impact of spironolactone in diabetic nephropathy.
    Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, Parving HH.
    Kidney Int; 2005 Dec 14; 68(6):2829-36. PubMed ID: 16316360
    [Abstract] [Full Text] [Related]

  • 19. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH.
    Kidney Int; 2016 Sep 14; 90(3):696-704. PubMed ID: 27350174
    [Abstract] [Full Text] [Related]

  • 20. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U, García de Vinuesa S, Goicoechea M, Macías N, Santos A, Perez de Jose A, Verde E, Yuste C, Luño J.
    Nephrology (Carlton); 2015 Aug 14; 20(8):567-71. PubMed ID: 25818266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.